Mycobacterium vaccae immunotherapy for treating tuberculosis.
BACKGROUND
Some authorities have advocated Mycobacterium vaccae immunotherapy for treating tuberculosis and other infections caused by mycobacteria.


OBJECTIVE
To assess the effects of Mycobacterium vaccae as an adjunct to chemotherapy for treating tuberculosis.


METHODS
We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials register, Medline, Embase and reference lists of articles. We also contacted organisations and individuals working in the field.


METHODS
Randomised and quasi-randomised trials using whole, killed Mycobacterium vaccae for patients with tuberculosis.


METHODS
One reviewer assessed trial quality and extracted data.


RESULTS
Six trials met the inclusion criteria. There was no effect on mortality (three trials, OR 1.01, 95% CI 0.51 to 1.99). No consistent effect on sputum negativity or sputum culture was shown. Most immunotherapy recipients experienced local adverse reactions (two trials, OR 18.2, 95% CI 9 to 37), some of which progressed to ulceration and scarring.


CONCLUSIONS
Immunotherapy with Mycobacterium vaccae does not appear to benefit patients with tuberculosis.
Department of Medicine, Baylor College of Medicine, Fondren-Brown Building, 6565 Fannin St, Houston, TX, USA, 77030. guyd@bcm.tmc.edu
B
B
de
P
P
Garner
D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009161:Mycobacterium / Q000276:immunology*; D016032:Randomized Controlled Trials as Topic; D014376:Tuberculosis / Q000276:immunology / Q000628:therapy*; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000628:therapy